K

Kiniksa Pharmaceuticals Ltd
D

KNSA

27.080
USD
0.72
(2.73%)
مغلق
حجم التداول
41,763
الربح لكل سهم
0
العائد الربحي
-
P/E
-113
حجم السوق
1,976,053,786
أصول ذات صلة
A
ASND
-3.120
(-1.86%)
164.370 USD
ICLR
ICLR
2.680
(1.43%)
189.760 USD
M
MCRB
-1.170
(-8.14%)
13.200 USD
M
MGNX
-0.03500
(-2.03%)
1.68500 USD
O
OMER
0.32500
(8.46%)
4.16500 USD
R
RDFN
0
(0.00%)
0 USD
S
SGMO
0.01640
(2.80%)
0.60240 USD
TEVA
TEVA
-0.025
(-0.15%)
16.520 USD
VRTX
VRTX
-8.76
(-1.87%)
460.82 USD
المزيد
الأخبار المقالات

العنوان: Kiniksa Pharmaceuticals International plc

القطاع: Healthcare
الصناعة: Drug Manufacturers - Specialty & Generic
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.